Image

Global Chronic Spontaneous Urticaria Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Chronic Spontaneous Urticaria Market, By Treatment (Medication, Phototherapy, and Others), Diagnosis (Physical Examination, Blood Test, Allergy Test and Others), Route of Administration (Oral, Topical, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

 

Chronic Spontaneous Urticaria Market

Market Analysis and Size

In recent years, the chronic spontaneous urticaria market is anticipated to grow rapidly during the forecast period owing to the high prevalence of urticaria. Urticaria is a skin disorder that is characterized by hives and angioedema. Chronic spontaneous urticaria is described as urticaria symptoms that last for at least 6 weeks. In around 45 percent of patients, it is linked to autoimmunity. Although treatment can be challenging, high-dose non-sedating antihistamines should be used as a first line of defense; 4-6 tablets per day may be required.

Data Bridge Market Research analyses that the chronic spontaneous urticaria market was valued at USD 603.41 million in 2021 and is expected to reach USD 1,193.54 million by 2029, registering a CAGR of 8.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Chronic Spontaneous Urticaria (CSU) is a common and bothersome skin illness characterized by red, raised, itchy, and occasionally painful hives or wheals (raised rash or patches) on the skin with no evident reason. When hives appear, take cetirizine, fexofenadine, or loratadine, which are non-drowsy antihistamines. Using sedating antihistamines such as cyproheptadine, diphenhydramine, doxepin, or hydroxyzine at night.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Medication, Phototherapy, and Others), Diagnosis (Physical Examination, Blood Test, Allergy Test and Others), Route of Administration (Oral, Topical, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Hikma Pharmaceuticals Plc (UK), LEO Pharma A/S (Denmark), WOCKHARDT (Mumbai), AstraZeneca (UK), AbbVie Inc. (US), Johnson & Johnson Private Limited (US), Cipla Inc. (US)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Chronic Spontaneous Urticaria Market Dynamics

Drivers

  • Increasing prevalence of urticaria

The rising prevalence of urticaria is a primary driver of the chronic spontaneous urticaria market's growth. Changing environment and increasing cases of skin infections are the factors that will enhance the prevalence of urticaria and influence the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of chronic spontaneous urticaria market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the chronic spontaneous urticaria market. Additionally, high disposable income and increasing alcohol consumption will result in the expansion of chronic spontaneous urticaria market. Along with this, rising geriatric population and changing lifestyle of people will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for chronic spontaneous urticaria market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the chronic spontaneous urticaria market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of chronic spontaneous urticaria will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the chronic spontaneous urticaria market. Additionally, strict regulations and the dearth of awareness about treatment for this illness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Chronic spontaneous urticaria market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic spontaneous urticaria market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

It's anticipated that 0.5-1 percent of the UK population is afflicted. CSU can have an impact on both children and adults. Females are twice as likely to be diagnosed with CSU as males. It affects older children and teenagers more than neonates. Symptoms are more common in people between the ages of 20 and 40.

Chronic spontaneous urticaria market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Chronic Spontaneous Urticaria Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of chronic spontaneous urticaria in recent months.

Recent Development

  • In December 2021, Novartis had announced the top-line results from PEARL 1 and PEARL 2 Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU). It was discovered that the studies' primary goals of superiority for ligelizumab over placebo at Week 12 were met, but not for omalizumab. Ligelizumab, a high-affinity anti-IgE antibody, was found to be superior to placebo at Week 12 in the PEARL 1 and PEARL 2 Phase III studies, but not to omalizumab.

Global Chronic Spontaneous Urticaria Market Scope

The chronic spontaneous urticaria market is segmented on the basis of treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Medication
  • Phototherapy
  • Others

On the basis of treatment, the global chronic spontaneous urticaria market is segmented into medication, phototherapy and others. Medication can be further segmented into H2 blockers, corticosteroids, antidepressants, monoclonal antibodies and others.

Diagnosis

  • Physical Examination
  • Blood Test
  • Allergy Test
  • Others

On the basis of diagnosis, the chronic spontaneous urticaria market is segmented into physical examination, blood test, allergy test, and others.

Route of Administration

  • Oral
  • Topical
  • Parenteral
  • Others

The route of administration segment for the chronic spontaneous urticaria market is segmented into oral, topical, parenteral and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the chronic spontaneous urticaria market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the chronic spontaneous urticaria market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Pipeline Analysis

UB-221, GBR 310, UCB8600, Ligelizumab, Dupilumab, Antolimab, CDX-0159, LY3454738 and GI-301 are among the medicines in various stages of development for chronic spontaneous urticaria.

Chronic Spontaneous Urticaria Market Regional Analysis/Insights

The Chronic spontaneous urticaria market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Chronic spontaneous urticaria market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the chronic spontaneous urticaria market because of the growing prevalence of chronic spontaneous urticaria in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Chronic Spontaneous Urticaria Market Share Analysis

The Chronic spontaneous urticaria market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chronic spontaneous urticaria market.

Some of the major players operating in the chronic spontaneous urticaria market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Aurobindo Pharma (Hyderabad)
  • Lupin (Mumbai)
  • Hikma Pharmaceuticals Plc (UK)
  • LEO Pharma A/S (Denmark)
  • WOCKHARDT (Mumbai)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)  

Research Methodology: Global Chronic Spontaneous Urticaria Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Chronic Spontaneous Urticaria Market is expected USD 1,193.54 million by 2029.
The Chronic Spontaneous Urticaria Market is to grow at a CAGR of 8.90% during the forecast period of 2022 to 2029
The expansion of the Global Chronic Spontaneous Urticaria Market will be fueled by the increasing alcohol consumption and rising prevalence of urticaria. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global chronic spontaneous urticaria market.
The major players operating in the Chronic Spontaneous Urticaria Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Hikma Pharmaceuticals Plc (UK), LEO Pharma A/S (Denmark), WOCKHARDT (Mumbai), AstraZeneca (UK), AbbVie Inc. (US), Johnson & Johnson Private Limited (US), Cipla Inc. (US).